HIV-1 resistance patterns vary by prior regimen and geographic region in this substudy
HIV drug resistance patterns vary by region and prior treatment history
This substudy examined HIV-1 drug resistance mutations in people failing first-line therapy across 14 countries.
HIV drug resistance varies by region and prior treatment. Subtype C dominates, but resistance to common drugs is high. This matters for choo…
Integrase inhibitor regimen showed non-inferiority and fewer adverse events versus boosted protease inhibitor in advanced HIV
Integrase Inhibitors Show Lower Event Rates Than Boosted Protease Inhibitors in Advanced HIV
This trial compared an integrase inhibitor regimen with a boosted protease inhibitor regimen in therapy-naive adults with advanced HIV disea…
A trial of 447 therapy-naive adults with advanced HIV found fewer drug-related side effects with an integrase inhibitor regimen compared to …
Switching from EFV/TDF/3TC to B/F/TAF or DTG/3TC in virologically suppressed PLWH shows no significant between-group metabolic differences over 24 months
Switching HIV drugs showed similar metabolic changes over two years in this real-world study
This retrospective real-world study evaluated 326 virologically suppressed persons with HIV (PLWH) switching from efavirenz/tenofovir disopr…
Switching HIV drugs caused similar weight gain and metabolic shifts over two years, meaning lifestyle factors matter more than the specific …
Cochrane review: injectable lenacapavir cuts HIV infections versus oral PrEP at 52 weeks
One Shot Saves You From HIV For Six Months
This Cochrane systematic review and meta-analysis of two randomised controlled trials (8660 participants) compared six-monthly subcutaneous …
A single shot under the skin protects against HIV for six months, solving the daily pill problem for millions at risk.
CDC updates recommendations for HIV nonoccupational postexposure prophylaxis
CDC updates recommendations for HIV prevention medication after possible exposure
The CDC has issued updated recommendations for antiretroviral postexposure prophylaxis following nonoccupational HIV exposure.
The CDC updated its guidance on taking HIV prevention medication after a possible exposure to help doctors give the most current advice.
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…